BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 15743502)

  • 1. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.
    Benoy IH; Salgado R; Elst H; Van Dam P; Weyler J; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Breast Cancer Res; 2005; 7(2):R210-9. PubMed ID: 15743502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour.
    Colpaert C; Vermeulen P; Jeuris W; van Beest P; Goovaerts G; Weyler J; Van Dam P; Dirix L; Van Marck E
    J Pathol; 2001 Apr; 193(4):442-9. PubMed ID: 11276002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study.
    Langer I; Guller U; Koechli OR; Berclaz G; Singer G; Schaer G; Fehr MK; Hess T; Oertli D; Bronz L; Schnarwyler B; Wight E; Uehlinger U; Infanger E; Burger D; Zuber M;
    Ann Surg Oncol; 2007 Jun; 14(6):1896-903. PubMed ID: 17356955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
    Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
    Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.
    Masuda TA; Kataoka A; Ohno S; Murakami S; Mimori K; Utsunomiya T; Inoue H; Tsutsui S; Kinoshita J; Masuda N; Moriyama N; Mori M
    Int J Oncol; 2005 Mar; 26(3):721-30. PubMed ID: 15703829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification.
    Noguchi S; Aihara T; Motomura K; Inaji H; Imaoka S; Koyama H
    Am J Pathol; 1996 Feb; 148(2):649-56. PubMed ID: 8579127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
    Saha S; Ali S; Ghanem M; Soni M; Wiese D; Arora M; Singh T; Iddings D
    Ann Surg Oncol; 2009 Feb; 16(2):276-80. PubMed ID: 19050967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
    Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
    Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer.
    Van den Eynden GG; Van der Auwera I; Van Laere SJ; Trinh XB; Colpaert CG; van Dam P; Dirix LY; Vermeulen PB; Van Marck EA
    J Pathol; 2007 Sep; 213(1):56-64. PubMed ID: 17674348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years.
    Gebauer G; Fehm T; Merkle E; Jaeger W; Mitze M
    Anticancer Res; 2003; 23(5b):4319-24. PubMed ID: 14666645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow micrometastases and adjuvant treatment of breast cancer.
    Yu JJ; Brennan M; Christos P; Osborne MP; Hoda S; Simmons RM
    Breast J; 2004; 10(3):181-5. PubMed ID: 15125741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer.
    Benoy IH; Elst H; Philips M; Wuyts H; Van Dam P; Scharpé S; Van Marck E; Vermeulen PB; Dirix LY
    Clin Breast Cancer; 2006 Jun; 7(2):146-52. PubMed ID: 16800974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
    Diel IJ; Cote RJ
    Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
    Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiogenesis and micrometastases of regional lymph node in ovarian cancer].
    Liang YJ; Wu YZ; Gu MJ
    Ai Zheng; 2003 Feb; 22(2):185-8. PubMed ID: 12600297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus.
    Janni W; Hepp F; Strobl B; Rack B; Rjosk D; Kentenich C; Schindlbeck C; Hantschmann P; Pantel K; Sommer H; Braun S
    Cancer; 2003 Jan; 97(2):405-11. PubMed ID: 12518364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in the bone marrow of patients with breast cancer.
    Chavez-Macgregor M; Aviles-Salas A; Green D; Fuentes-Alburo A; Gómez-Ruiz C; Aguayo A
    Clin Cancer Res; 2005 Aug; 11(15):5396-400. PubMed ID: 16061853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients.
    Hansen S; Grabau DA; Sørensen FB; Bak M; Vach W; Rose C
    Clin Cancer Res; 2000 Jan; 6(1):139-46. PubMed ID: 10656442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients.
    Hansen S; Sørensen FB; Vach W; Grabau DA; Bak M; Rose C
    Histopathology; 2004 May; 44(5):428-36. PubMed ID: 15139990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.